Pegylated liposomal doxorubicin combined with trabectedin as a treatment option in uterine sarcomas: a single-institution retrospective analysis.
Magdalena SteinlechnerLaura StrobelKatharina LeitnerTeresa L PanBarin FerozChristian MarthAlain G ZeimetPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2024)
Our study found an overall clinical benefit for the combination of pegylated liposomal doxorubicin plus trabectedin in metastatic uterine sarcomas of 43% and appears to exhibit a favorable toxicity profile which allows prolonged administration of this regimen.